CD274 and hepatocellular carcinoma: However, the response pattern to the combination therapy of PD‐1/PD‐L1 inhibitor and antiangiogenic agent varies among HCC patients, since it may derive from tumor heterogeneity, metastasis locations, and tumor microenvironment.17, 18, 19